Modivcare Reports Fourth Quarter and Full Year 2021 Financial Results
Modivcare reported robust financial results for Q4 and full year 2021, with service revenue reaching $575.8 million in the fourth quarter, a 44% increase from $398.5 million in Q4 2020. Despite a loss from continuing operations of $31.5 million or $2.25 per share, adjusted EBITDA was $57.5 million. For the full year, revenues totaled $1,996.9 million, a 46% increase over $1,368.7 million in 2020. The company completed key acquisitions, enhancing its service offerings. However, significant losses related to the Matrix investment and rising costs were noted.
- Q4 service revenue increased by 44% year-over-year.
- Full year 2021 revenue rose 46% compared to 2020.
- Adjusted EBITDA increased to $57.5 million in Q4 2021.
- Completed acquisition of Care Finders and VRI, expanding service segments.
- Q4 loss from continuing operations was $31.5 million, primarily due to Matrix investment.
- Matrix reported a significant revenue decline of 33% year-over-year in Q4 2021.
- Operating income decreased to $20.3 million in Q4 2021, compared to $20.9 million in Q4 2020.
Fourth Quarter 2021 Highlights:
-
Service revenue of
, a$575.8 million 44% increase as compared to in the fourth quarter of 2020$398.5 million
-
Loss from continuing operations, net of tax, was
, or a loss of$31.5 million per common share, primarily as a result of the loss related to our Matrix investment of$2.25 , net of tax$36.8 million
-
Adjusted EBITDA of
, adjusted net income of$57.5 million and adjusted EPS of$29.8 million per diluted common share$2.11
-
Net cash provided by operating activities during the quarter of
, finishing the year with cash and cash equivalents of$12.1 million $133.1 million
Full Year 2021 Highlights:
-
Service revenue of
, a$1,996.9 million 46% increase as compared to in 2020$1,368.7 million
-
Loss from continuing operations, net of tax, was
, or$6.3 million per common share, primarily as result of the loss related to our Matrix investment of$0.45 , net of tax$38.3 million
-
Adjusted EBITDA of
, adjusted net income of$205.0 million and adjusted EPS of$112.2 million per diluted common share$7.89
-
Net cash provided by operating activities in 2021 of
$186.8 million
-
Completed
offering of Senior Unsecured Notes due 2029$500.0 million
-
Closed acquisition of
Care Finders Total Care LLC ("Care Finders"), expanding personal care segment
-
Closed acquisition of
VRI Intermediate Holdings, LLC ("VRI"), creating remote patient monitoring segment
-
Matrix, on a standalone basis, incurred a net loss of
and adjusted EBITDA of$122.9 million $67.5 million
Subsequent Events:
-
On
January 10, 2022 ,Modivcare announced the realignment of its home-based services under a new business division, Modivcare Home, which is composed of the Company’s personal care, remote monitoring, and nutritional meal delivery services.Jason E. Anderson has been promoted to lead the new division. The Company’s financial reporting segments have not been affected by this realignment.
-
On
February 3, 2022 ,Modivcare Inc. entered into a new senior secured revolving credit facility with total borrowing capacity of and a maturity date in$325.0 million February 2027 . This new facility was undrawn at closing and replaces the Company’s prior revolving credit facility.$225.0 million
“Over the past year, we have significantly expanded and enhanced our platform at
Fourth Quarter 2021 Results
For the fourth quarter of 2021, the Company reported revenue of
The quarter-over-quarter increase in revenue was primarily driven by an additional
Operating income was
Adjusted EBITDA was
Adjusted Net Income in the fourth quarter of 2021 was
Adjusted EBITDA and adjusted net income increased in the fourth quarter of 2021 due to contributions from the Care Finders and VRI acquisitions, as well as a full quarter contribution from the acquisition of Simplura in
Full Year 2021 Results
For the full year 2021, the Company reported revenue of
Operating income was
Adjusted EBITDA for 2021 was
Adjusted net income for 2021 was
Matrix Medical Network
For the fourth quarter of 2021, Matrix’s revenue was
Matrix’s revenue and Adjusted EBITDA in the fourth quarter 2021 were negatively impacted by lower revenue in its Clinical Solutions segment, as the company experienced significant benefits in the prior year from employee health and wellness services related to COVID-19 testing and vaccines in this segment. This was partially offset by favorable pricing and mix benefits in the Clinical Care segment during the fourth quarter of 2021.
For the full year 2021, Matrix's revenue was
As of
Investor Presentation and Conference Call
US toll-free: 1 (877) 423 9820
International: 1 (201) 493 6749
You may also access the conference call via webcast at investors.modivcare.com, where the call also will be archived.
About
Non-GAAP Financial Measures and Adjustments
In addition to the financial measures prepared in accordance with generally accepted accounting principles in
Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because they are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on our reported financial results. The presentation of non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the most directly comparable financial measures prepared in accordance with GAAP. We urge you to review the reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are frequently identified by the use of terms such as “may,” “will,” “should,” “expect,” “believe,” “estimate,” “intend,” and similar words indicating possible future expectations, events or actions. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond our ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein, including but not limited to: government or private insurance program funding reductions or limitations; alternative payment models or the transition of Medicaid and Medicare beneficiaries to Managed Care Organizations, or MCOs; our inability to control reimbursement rates received for our services; cost containment initiatives undertaken by private third-party payors; the effects of a public health emergency; inadequacies in, or security breaches of, our information technology systems, including the systems intended to protect our clients’ privacy and confidential information; any changes in the funding, financial viability or our relationships with our payors; pandemic infectious diseases, including the COVID-19 pandemic; disruptions to our contact center operations caused by health epidemics or pandemics like COVID-19; delays in collection, or non-collection, of our accounts receivable, particularly during any business integration; an impairment of our long-lived assets; any failure to maintain or to develop further reliable, efficient and secure information technology systems; an inability to attract and retain qualified employees; any acquisition or acquisition integration efforts; our contracts not surviving until the end of their stated terms, or not being renewed or extended; our failure to compete effectively in the marketplace; our not being awarded contracts through the government’s requests for proposals process, or our awarded contracts not being profitable; any failure to satisfy our contractual obligations or to maintain existing pledged performance and payment bonds; a failure to estimate accurately the cost of performing our contracts; any misclassification of the drivers we engage as independent contractors rather than as employees; significant interruptions in our communication and data services; not successfully executing on our strategies in the face of our competition; any inability to maintain relationships with existing patient referral sources; any failure to obtain the consent of the
The Company has provided additional information about the risks facing our business in our annual report on Form 10-K and subsequent filings most recently filed with the
--financial tables to follow--
|
||||||||||||||||
Unaudited Condensed Consolidated Statements of Operations |
||||||||||||||||
(in thousands except share and per share data) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three months ended |
|
Year ended |
||||||||||||
|
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
|
|
|
|
|
|
||||||||
Service revenue, net |
|
$ |
575,775 |
|
|
$ |
398,509 |
|
|
$ |
1,996,892 |
|
|
$ |
1,368,675 |
|
Grant income |
|
|
1,941 |
|
|
|
— |
|
|
|
5,441 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
Service expense |
|
|
445,128 |
|
|
|
314,485 |
|
|
|
1,584,298 |
|
|
|
1,078,795 |
|
General and administrative expense |
|
|
91,995 |
|
|
|
54,104 |
|
|
|
271,266 |
|
|
|
140,539 |
|
Depreciation and amortization |
|
|
20,331 |
|
|
|
8,984 |
|
|
|
56,998 |
|
|
|
26,183 |
|
Total operating expenses |
|
|
557,454 |
|
|
|
377,573 |
|
|
|
1,912,562 |
|
|
|
1,245,517 |
|
|
|
|
|
|
|
|
|
|
||||||||
Operating income |
|
|
20,262 |
|
|
|
20,936 |
|
|
|
89,771 |
|
|
|
123,158 |
|
|
|
|
|
|
|
|
|
|
||||||||
Other expenses: |
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
|
14,669 |
|
|
|
15,481 |
|
|
|
49,081 |
|
|
|
17,599 |
|
Income from continuing operations before
|
|
|
5,593 |
|
|
|
5,455 |
|
|
|
40,690 |
|
|
|
105,559 |
|
Provision for income taxes |
|
|
232 |
|
|
|
5,626 |
|
|
|
8,729 |
|
|
|
22,356 |
|
Equity in net (income) loss of investee, net of tax |
|
|
36,826 |
|
|
|
2,734 |
|
|
|
38,250 |
|
|
|
(6,411 |
) |
Income (loss) from continuing operations, net of tax |
|
|
(31,465 |
) |
|
|
(2,905 |
) |
|
|
(6,289 |
) |
|
|
89,614 |
|
Loss from discontinued operations, net of tax |
|
|
(64 |
) |
|
|
(160 |
) |
|
|
(296 |
) |
|
|
(778 |
) |
Net income (loss) |
|
$ |
(31,529 |
) |
|
$ |
(3,065 |
) |
|
$ |
(6,585 |
) |
|
$ |
88,836 |
|
|
|
|
|
|
|
|
|
|
||||||||
Net income (loss) attributable to common stockholders |
|
$ |
(31,529 |
) |
|
$ |
(3,065 |
) |
|
$ |
(6,585 |
) |
|
$ |
32,471 |
|
|
|
|
|
|
|
|
|
|
||||||||
Basic earnings (loss) per common share: |
|
|
|
|
|
|
|
|
||||||||
Continuing operations |
|
$ |
(2.25 |
) |
|
$ |
(0.21 |
) |
|
$ |
(0.45 |
) |
|
$ |
2.45 |
|
Discontinued operations |
|
|
— |
|
|
|
(0.01 |
) |
|
|
(0.02 |
) |
|
|
(0.06 |
) |
Basic earnings (loss) per common share |
|
$ |
(2.25 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.47 |
) |
|
$ |
2.39 |
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings (loss) per common share: |
|
|
|
|
|
|
|
|
||||||||
Continuing operations |
|
$ |
(2.25 |
) |
|
$ |
(0.21 |
) |
|
$ |
(0.45 |
) |
|
$ |
2.43 |
|
Discontinued operations |
|
|
— |
|
|
|
(0.01 |
) |
|
|
(0.02 |
) |
|
|
(0.06 |
) |
Diluted earnings (loss) per common share |
|
$ |
(2.25 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.47 |
) |
|
$ |
2.37 |
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted-average number of common shares outstanding: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
|
13,998,487 |
|
|
|
14,159,965 |
|
|
|
14,054,060 |
|
|
|
13,567,323 |
|
Diluted |
|
|
13,998,487 |
|
|
|
14,159,965 |
|
|
|
14,054,060 |
|
|
|
13,683,308 |
|
|
||||||
Unaudited Condensed Consolidated Balance Sheets |
||||||
(in thousands) |
||||||
|
|
|
|
|
||
|
|
|
||||
|
|
|
2021 |
|
|
2020 |
Assets |
|
|
|
|
||
Current assets: |
|
|
|
|
||
Cash and cash equivalents |
|
$ |
133,139 |
|
$ |
183,281 |
Accounts receivable, net of allowance |
|
|
233,121 |
|
|
197,943 |
Other current assets (1) |
|
|
43,574 |
|
|
38,304 |
Total current assets |
|
|
409,834 |
|
|
419,528 |
Operating lease right-of-use assets |
|
|
43,750 |
|
|
30,928 |
Property and equipment, net |
|
|
53,549 |
|
|
27,544 |
|
|
|
1,415,000 |
|
|
790,579 |
Equity investment |
|
|
83,069 |
|
|
137,466 |
Other long-term assets |
|
|
22,223 |
|
|
19,868 |
Total assets |
|
$ |
2,027,425 |
|
$ |
1,425,913 |
|
|
|
|
|
||
Liabilities and stockholders' equity |
||||||
Current liabilities: |
|
|
|
|
||
Accounts payable |
|
$ |
8,690 |
|
$ |
8,464 |
Accrued contract payables |
|
|
281,586 |
|
|
101,705 |
Accrued expenses and other current liabilities |
|
|
119,563 |
|
|
116,620 |
Accrued transportation costs |
|
|
103,294 |
|
|
79,674 |
Current portion of operating lease liabilities |
|
|
9,873 |
|
|
8,277 |
Deferred revenue |
|
|
4,228 |
|
|
2,923 |
Total current liabilities |
|
|
527,234 |
|
|
317,663 |
Long-term debt, net of deferred financing costs |
|
|
975,225 |
|
|
485,980 |
Operating lease liabilities, less current portion |
|
|
34,524 |
|
|
23,437 |
Long-term contracts payables |
|
|
— |
|
|
72,183 |
Other long-term liabilities (2) |
|
|
117,175 |
|
|
115,039 |
Total liabilities |
|
|
1,654,158 |
|
|
1,014,302 |
|
|
|
|
|
||
Stockholders' equity |
|
|
|
|
||
Stockholders' equity |
|
|
373,267 |
|
|
411,611 |
Total liabilities and stockholders' equity |
|
$ |
2,027,425 |
|
$ |
1,425,913 |
(1) Includes inventories, other receivables, prepaid expenses and other current assets and short-term restricted cash.
(2) Includes other long-term liabilities and deferred tax liabilities.
|
||||||||
Unaudited Condensed Consolidated Statements of Cash Flows |
||||||||
(in thousands) |
||||||||
|
|
|
|
|
||||
|
|
Year ended |
||||||
|
|
|
2021 |
|
|
|
2020 |
|
Operating activities |
|
|
|
|
||||
Net income (loss) |
|
$ |
(6,585 |
) |
|
$ |
88,836 |
|
Depreciation and amortization |
|
|
56,998 |
|
|
|
26,182 |
|
Stock-based compensation |
|
|
5,904 |
|
|
|
3,930 |
|
Equity in net (income) loss of investee |
|
|
53,092 |
|
|
|
(8,860 |
) |
Deferred income taxes |
|
|
(17,691 |
) |
|
|
11,919 |
|
Reduction of right of use asset |
|
|
11,330 |
|
|
|
9,238 |
|
Other non-cash items |
|
|
434 |
|
|
|
(2,609 |
) |
Changes in working capital |
|
|
83,358 |
|
|
|
219,799 |
|
Net cash provided by operating activities |
|
|
186,840 |
|
|
|
348,435 |
|
|
|
|
|
|
||||
Investing activities |
|
|
|
|
||||
Purchase of property and equipment |
|
|
(21,316 |
) |
|
|
(12,150 |
) |
Acquisitions, net of cash acquired |
|
|
(664,309 |
) |
|
|
(622,862 |
) |
Net cash used in investing activities |
|
|
(685,625 |
) |
|
|
(635,012 |
) |
|
|
|
|
|
||||
Financing activities |
|
|
|
|
||||
Proceeds from debt |
|
|
625,000 |
|
|
|
737,000 |
|
Repayment of debt |
|
|
(125,000 |
) |
|
|
(237,000 |
) |
Repurchase of common stock, for treasury |
|
|
(39,994 |
) |
|
|
(10,186 |
) |
Payment of debt issuance costs |
|
|
(13,486 |
) |
|
|
(15,633 |
) |
Proceeds from common stock issued pursuant to stock option exercise |
|
|
3,227 |
|
|
|
25,413 |
|
Restricted stock surrendered for employee tax payment |
|
|
(896 |
) |
|
|
(267 |
) |
Preferred stock redemption payment |
|
|
— |
|
|
|
(88,771 |
) |
Preferred stock dividends |
|
|
— |
|
|
|
(1,987 |
) |
Other financing activities |
|
|
— |
|
|
|
(309 |
) |
Net cash provided by financing activities |
|
|
448,851 |
|
|
|
408,260 |
|
|
|
|
|
|
||||
Net change in cash and cash equivalents |
|
|
(49,934 |
) |
|
|
121,683 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
183,356 |
|
|
|
61,673 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
133,422 |
|
|
$ |
183,356 |
|
|
||||||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
||||||||||||||||||
Segment Information and Adjusted EBITDA |
||||||||||||||||||
(in thousands) |
||||||||||||||||||
|
Three Months Ended |
|||||||||||||||||
|
NEMT |
|
Personal
|
|
RPM |
|
Matrix
|
|
Total
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||
Service revenue, net |
$ |
402,528 |
|
|
$ |
157,194 |
|
|
$ |
16,053 |
|
$ |
— |
|
|
$ |
575,775 |
|
Grant income |
|
— |
|
|
|
1,941 |
|
|
|
— |
|
|
— |
|
|
|
1,941 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|||||||||
Service expense |
|
316,715 |
|
|
|
123,575 |
|
|
|
4,838 |
|
|
— |
|
|
|
445,128 |
|
General and administrative expense |
|
61,626 |
|
|
|
24,814 |
|
|
|
5,555 |
|
|
— |
|
|
|
91,995 |
|
Depreciation and amortization |
|
7,314 |
|
|
|
9,036 |
|
|
|
3,981 |
|
|
— |
|
|
|
20,331 |
|
Total operating expenses |
|
385,655 |
|
|
|
157,425 |
|
|
|
14,374 |
|
|
— |
|
|
|
557,454 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Operating income |
|
16,873 |
|
|
|
1,710 |
|
|
|
1,679 |
|
|
— |
|
|
|
20,262 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Other expenses: |
|
|
|
|
|
|
|
|
|
|||||||||
Interest expense, net |
|
14,669 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
14,669 |
|
Income from continuing operations before
|
|
2,204 |
|
|
|
1,710 |
|
|
|
1,679 |
|
|
— |
|
|
|
5,593 |
|
Provision (benefit) for income taxes |
|
(48 |
) |
|
|
(65 |
) |
|
|
345 |
|
|
— |
|
|
|
232 |
|
Equity in net loss of investee, net of tax |
|
— |
|
|
|
— |
|
|
|
— |
|
|
36,826 |
|
|
|
36,826 |
|
Income (loss) from continuing operations, net of tax |
|
2,252 |
|
|
|
1,775 |
|
|
|
1,334 |
|
|
(36,826 |
) |
|
|
(31,465 |
) |
|
|
|
|
|
|
|
|
|
|
|||||||||
Interest expense, net |
|
14,669 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
14,669 |
|
Provision (benefit) for income taxes |
|
(48 |
) |
|
|
(65 |
) |
|
|
345 |
|
|
— |
|
|
|
232 |
|
Depreciation and amortization |
|
7,314 |
|
|
|
9,036 |
|
|
|
3,981 |
|
|
— |
|
|
|
20,331 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
EBITDA |
|
24,187 |
|
|
|
10,746 |
|
|
|
5,660 |
|
|
(36,826 |
) |
|
|
3,767 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Restructuring and related charges (1) |
|
9,666 |
|
|
|
304 |
|
|
|
— |
|
|
— |
|
|
|
9,970 |
|
Transaction costs (2) |
|
2,968 |
|
|
|
3,463 |
|
|
|
721 |
|
|
— |
|
|
|
7,152 |
|
Cash settled equity |
|
20 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
20 |
|
Stock-based compensation |
|
1,068 |
|
|
|
(58 |
) |
|
|
— |
|
|
— |
|
|
|
1,010 |
|
COVID-19 related costs, net of grant income |
|
101 |
|
|
|
(1,340 |
) |
|
|
— |
|
|
— |
|
|
|
(1,239 |
) |
Equity in net loss of investee, net of taxes |
|
— |
|
|
|
— |
|
|
|
— |
|
|
36,826 |
|
|
|
36,826 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Adjusted EBITDA |
$ |
38,010 |
|
|
$ |
13,115 |
|
|
$ |
6,381 |
|
$ |
— |
|
|
$ |
57,506 |
|
(1) Restructuring and related charges include professional fees for strategic initiatives of
(2) Transaction costs consist of fees incurred in the acquisitions of Care Finders and VRI.
|
||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
||||||||||||||
Segment Information and Adjusted EBITDA |
||||||||||||||
(in thousands) |
||||||||||||||
|
Three Months Ended |
|||||||||||||
|
NEMT |
|
Personal Care |
|
Matrix
|
|
Total Continuing
|
|||||||
|
|
|
|
|
|
|
|
|||||||
Service revenue, net |
$ |
344,539 |
|
|
$ |
53,970 |
|
$ |
— |
|
|
$ |
398,509 |
|
|
|
|
|
|
|
|
|
|||||||
Operating expenses: |
|
|
|
|
|
|
|
|||||||
Service expense |
|
271,978 |
|
|
|
42,507 |
|
|
— |
|
|
|
314,485 |
|
General and administrative expense |
|
46,776 |
|
|
|
7,328 |
|
|
— |
|
|
|
54,104 |
|
Depreciation and amortization |
|
7,317 |
|
|
|
1,667 |
|
|
— |
|
|
|
8,984 |
|
Total operating expenses |
|
326,071 |
|
|
|
51,502 |
|
|
— |
|
|
|
377,573 |
|
|
|
|
|
|
|
|
|
|||||||
Operating income |
|
18,468 |
|
|
|
2,468 |
|
|
— |
|
|
|
20,936 |
|
|
|
|
|
|
|
|
|
|||||||
Other expenses: |
|
|
|
|
|
|
|
|||||||
Interest expense, net |
|
15,481 |
|
|
|
— |
|
|
— |
|
|
|
15,481 |
|
Income from continuing operations before income taxes
|
|
2,987 |
|
|
|
2,468 |
|
|
— |
|
|
|
5,455 |
|
Provision for income taxes |
|
4,548 |
|
|
|
1,078 |
|
|
— |
|
|
|
5,626 |
|
Equity in net loss of investee, net of tax |
|
— |
|
|
|
— |
|
|
2,734 |
|
|
|
2,734 |
|
Income (loss) from continuing operations, net of tax |
|
(1,561 |
) |
|
|
1,390 |
|
|
(2,734 |
) |
|
|
(2,905 |
) |
|
|
|
|
|
|
|
|
|||||||
Interest expense, net |
|
15,481 |
|
|
|
— |
|
|
— |
|
|
|
15,481 |
|
Provision for income taxes |
|
4,548 |
|
|
|
1,078 |
|
|
— |
|
|
|
5,626 |
|
Depreciation and amortization |
|
7,317 |
|
|
|
1,667 |
|
|
— |
|
|
|
8,984 |
|
|
|
|
|
|
|
|
|
|||||||
EBITDA |
|
25,785 |
|
|
|
4,135 |
|
|
(2,734 |
) |
|
|
27,186 |
|
|
|
|
|
|
|
|
|
|||||||
Restructuring and related charges (1) |
|
2,901 |
|
|
|
— |
|
|
— |
|
|
|
2,901 |
|
Transaction costs (2) |
|
7,919 |
|
|
|
— |
|
|
— |
|
|
|
7,919 |
|
Cash settled equity (3) |
|
9,180 |
|
|
|
— |
|
|
— |
|
|
|
9,180 |
|
Stock-based compensation (3) |
|
929 |
|
|
|
— |
|
|
— |
|
|
|
929 |
|
COVID-19 related costs |
|
200 |
|
|
|
655 |
|
|
— |
|
|
|
855 |
|
Equity in net loss of investee, net of taxes |
|
— |
|
|
|
— |
|
|
2,734 |
|
|
|
2,734 |
|
|
|
|
|
|
|
|
|
|||||||
Adjusted EBITDA |
$ |
46,914 |
|
|
$ |
4,790 |
|
$ |
— |
|
|
$ |
51,704 |
|
(1) Restructuring and related charges include professional fees for strategic initiatives of
(2) Transaction costs consist of fees incurred in the acquisition of Simplura.
(3) Adjusted EBITDA for Q4 of 2020 was recast to show the impact of stock-based compensation and cash settled equity, which the Company is now including for purposes of this calculation.
|
|||||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
|||||||||||||||||
Segment Information and Adjusted EBITDA |
|||||||||||||||||
(in thousands) |
|||||||||||||||||
|
Twelve Months Ended |
||||||||||||||||
|
NEMT |
|
Personal
|
|
RPM |
|
Matrix
|
|
Total
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
Service revenue, net |
$ |
1,483,696 |
|
$ |
495,579 |
|
|
$ |
17,617 |
|
$ |
— |
|
|
$ |
1,996,892 |
|
Grant income |
|
— |
|
|
5,441 |
|
|
|
— |
|
|
— |
|
|
|
5,441 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||||||
Service expense |
|
1,186,185 |
|
|
392,508 |
|
|
|
5,605 |
|
|
— |
|
|
|
1,584,298 |
|
General and administrative expense |
|
195,332 |
|
|
70,163 |
|
|
|
5,771 |
|
|
— |
|
|
|
271,266 |
|
Depreciation and amortization |
|
29,058 |
|
|
23,759 |
|
|
|
4,181 |
|
|
— |
|
|
|
56,998 |
|
Total operating expenses |
|
1,410,575 |
|
|
486,430 |
|
|
|
15,557 |
|
|
— |
|
|
|
1,912,562 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating income |
|
73,121 |
|
|
14,590 |
|
|
|
2,060 |
|
|
— |
|
|
|
89,771 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Other expenses: |
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
49,081 |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
49,081 |
|
Income from continuing operations before income
|
|
24,040 |
|
|
14,590 |
|
|
|
2,060 |
|
|
— |
|
|
|
40,690 |
|
Provision for income taxes |
|
4,978 |
|
|
3,299 |
|
|
|
452 |
|
|
— |
|
|
|
8,729 |
|
Equity in net loss of investee, net of tax |
|
— |
|
|
— |
|
|
|
— |
|
|
38,250 |
|
|
|
38,250 |
|
Income (loss) from continuing operations, net of tax |
|
19,062 |
|
|
11,291 |
|
|
|
1,608 |
|
|
(38,250 |
) |
|
|
(6,289 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
49,081 |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
49,081 |
|
Provision for income taxes |
|
4,978 |
|
|
3,299 |
|
|
|
452 |
|
|
— |
|
|
|
8,729 |
|
Depreciation and amortization |
|
29,058 |
|
|
23,759 |
|
|
|
4,181 |
|
|
— |
|
|
|
56,998 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
EBITDA |
|
102,179 |
|
|
38,349 |
|
|
|
6,241 |
|
|
(38,250 |
) |
|
|
108,519 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
|
20,881 |
|
|
304 |
|
|
|
— |
|
|
— |
|
|
|
21,185 |
|
Transaction costs (2) |
|
17,937 |
|
|
6,930 |
|
|
|
721 |
|
|
— |
|
|
|
25,588 |
|
Cash settled equity |
|
9,165 |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
9,165 |
|
Stock-based compensation |
|
4,775 |
|
|
18 |
|
|
|
— |
|
|
— |
|
|
|
4,793 |
|
COVID-19 related costs, net of grant income |
|
719 |
|
|
(3,211 |
) |
|
|
— |
|
|
— |
|
|
|
(2,492 |
) |
Equity in net loss of investee, net of tax |
|
— |
|
|
— |
|
|
|
— |
|
|
38,250 |
|
|
|
38,250 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA |
$ |
155,656 |
|
$ |
42,390 |
|
|
$ |
6,962 |
|
$ |
— |
|
|
$ |
205,008 |
|
(1) Restructuring and related charges include professional fees for strategic initiatives of
(2) Transaction costs consist of fees incurred in the acquisitions of Care Finders and VRI.
|
|||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
|||||||||||||
Segment Information and Adjusted EBITDA |
|||||||||||||
(in thousands) |
|||||||||||||
|
Twelve Months Ended |
||||||||||||
|
NEMT |
|
Personal Care |
|
Matrix
|
|
Total
|
||||||
|
|
|
|
|
|
|
|
||||||
Service revenue, net |
$ |
1,314,705 |
|
$ |
53,970 |
|
$ |
— |
|
|
$ |
1,368,675 |
|
|
|
|
|
|
|
|
|
||||||
Operating expenses: |
|
|
|
|
|
|
|
||||||
Service expense |
|
1,036,288 |
|
|
42,507 |
|
|
— |
|
|
|
1,078,795 |
|
General and administrative expense |
|
133,212 |
|
|
7,327 |
|
|
— |
|
|
|
140,539 |
|
Depreciation and amortization |
|
24,516 |
|
|
1,667 |
|
|
— |
|
|
|
26,183 |
|
Total operating expenses |
|
1,194,016 |
|
|
51,501 |
|
|
— |
|
|
|
1,245,517 |
|
|
|
|
|
|
|
|
|
||||||
Operating income |
|
120,689 |
|
|
2,469 |
|
|
— |
|
|
|
123,158 |
|
|
|
|
|
|
|
|
|
||||||
Other expenses: |
|
|
|
|
|
|
|
||||||
Interest expense, net |
|
17,599 |
|
|
— |
|
|
— |
|
|
|
17,599 |
|
Income from continuing operations before income
|
|
103,090 |
|
|
2,469 |
|
|
— |
|
|
|
105,559 |
|
Provision for income taxes |
|
21,279 |
|
|
1,077 |
|
|
— |
|
|
|
22,356 |
|
Equity in net income of investee, net of tax |
|
— |
|
|
— |
|
|
(6,411 |
) |
|
|
(6,411 |
) |
Income from continuing operations, net of tax |
|
81,811 |
|
|
1,392 |
|
|
6,411 |
|
|
|
89,614 |
|
|
|
|
|
|
|
|
|
||||||
Interest expense, net |
|
17,599 |
|
|
— |
|
|
— |
|
|
|
17,599 |
|
Provision for income taxes |
|
21,279 |
|
|
1,077 |
|
|
— |
|
|
|
22,356 |
|
Depreciation and amortization |
|
24,516 |
|
|
1,667 |
|
|
— |
|
|
|
26,183 |
|
|
|
|
|
|
|
|
|
||||||
EBITDA |
|
145,205 |
|
|
4,136 |
|
|
6,411 |
|
|
|
155,752 |
|
|
|
|
|
|
|
|
|
||||||
Restructuring and related charges (1) |
|
6,179 |
|
|
— |
|
|
— |
|
|
|
6,179 |
|
Transaction costs (2) |
|
12,619 |
|
|
— |
|
|
— |
|
|
|
12,619 |
|
Cash settled equity (3) |
|
16,071 |
|
|
— |
|
|
— |
|
|
|
16,071 |
|
Stock-based compensation (3) |
|
3,776 |
|
|
— |
|
|
— |
|
|
|
3,776 |
|
COVID-19 related costs |
|
549 |
|
|
655 |
|
|
— |
|
|
|
1,204 |
|
Equity in net income of investee, net of tax |
|
— |
|
|
— |
|
|
(6,411 |
) |
|
|
(6,411 |
) |
|
|
|
|
|
|
|
|
||||||
Adjusted EBITDA |
$ |
184,399 |
|
$ |
4,791 |
|
$ |
— |
|
|
$ |
189,190 |
|
(1) Restructuring and related charges include professional fees for strategic initiatives of
(2) Transaction costs consist of fees incurred in the acquisitions of Simplura and National MedTrans.
(3) Adjusted EBITDA for YTD of 2020 was recast to show the impact of stock-based compensation and cash settled equity, which the Company is now including for purposes of this calculation.
|
|||||||||||||||
Unaudited Summary Financial Information of |
|||||||||||||||
(in thousands) |
|||||||||||||||
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Revenue |
$ |
81,430 |
|
|
$ |
121,923 |
|
|
$ |
398,260 |
|
|
$ |
414,622 |
|
Operating expense |
|
76,665 |
|
|
|
114,396 |
|
|
|
365,674 |
|
|
|
327,616 |
|
Depreciation and amortization |
|
6,773 |
|
|
|
17,188 |
|
|
|
31,270 |
|
|
|
47,594 |
|
Operating income (loss) |
|
(2,008 |
) |
|
|
(9,661 |
) |
|
|
1,316 |
|
|
|
39,412 |
|
|
|
|
|
|
|
|
|
||||||||
Other expense (income) |
|
|
|
|
|
|
|
||||||||
|
|
111,358 |
|
|
|
— |
|
|
|
111,358 |
|
|
|
— |
|
Interest expense |
|
4,274 |
|
|
|
4,526 |
|
|
|
16,776 |
|
|
|
19,790 |
|
Provision (benefit) for income taxes |
|
(1,884 |
) |
|
|
(5,409 |
) |
|
|
(3,920 |
) |
|
|
4,484 |
|
Net income (loss) |
|
(115,756 |
) |
|
|
(8,778 |
) |
|
|
(122,898 |
) |
|
|
15,138 |
|
|
|
|
|
|
|
|
|
||||||||
Interest |
|
43.6 |
% |
|
|
43.6 |
% |
|
|
43.6 |
% |
|
|
43.6 |
% |
Net income (loss) - |
|
(50,470 |
) |
|
|
(3,827 |
) |
|
|
(53,584 |
) |
|
|
6,600 |
|
Management fee and other |
|
194 |
|
|
|
487 |
|
|
|
492 |
|
|
|
2,260 |
|
Equity in net gain (loss) of investee |
$ |
(50,276 |
) |
|
$ |
(3,340 |
) |
|
$ |
(53,092 |
) |
|
$ |
8,860 |
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
||||||||||
|
|
2021 |
|
|
|
2020 |
|
|
|
|
|
||||
Cash |
$ |
57,844 |
|
|
$ |
70,295 |
|
|
|
|
|
||||
Net debt (2) |
$ |
260,606 |
|
|
$ |
251,455 |
|
|
|
|
|
(1) The results of our equity method investment are excluded from the calculation of
(2) Net debt represents long-term debt including the current portion, excluding deferred financing costs, less cash.
|
||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
||||||||||||||
Adjusted EBITDA: Matrix Medical Network (1) |
||||||||||||||
(in thousands) |
||||||||||||||
|
Three Months Ended |
|
Twelve Months Ended |
|||||||||||
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
Revenue |
$ |
81,430 |
|
|
$ |
121,923 |
|
|
$ |
398,260 |
|
|
$ |
414,622 |
Operating expense |
|
76,665 |
|
|
|
114,396 |
|
|
|
365,674 |
|
|
|
327,616 |
Depreciation and amortization |
|
6,773 |
|
|
|
17,188 |
|
|
|
31,270 |
|
|
|
47,594 |
Operating income (loss) |
|
(2,008 |
) |
|
|
(9,661 |
) |
|
|
1,316 |
|
|
|
39,412 |
|
|
|
|
|
|
|
|
|||||||
Other expense (income) |
|
|
|
|
|
|
|
|||||||
|
|
111,358 |
|
|
|
— |
|
|
|
111,358 |
|
|
|
— |
Interest expense |
|
4,274 |
|
|
|
4,526 |
|
|
|
16,776 |
|
|
|
19,790 |
Provision (benefit) for income taxes |
|
(1,884 |
) |
|
|
(5,409 |
) |
|
|
(3,920 |
) |
|
|
4,484 |
Net income (loss) |
|
(115,756 |
) |
|
|
(8,778 |
) |
|
|
(122,898 |
) |
|
|
15,138 |
|
|
|
|
|
|
|
|
|||||||
Depreciation and amortization |
|
6,773 |
|
|
|
17,188 |
|
|
|
31,270 |
|
|
|
47,594 |
Interest expense |
|
4,274 |
|
|
|
4,526 |
|
|
|
16,776 |
|
|
|
19,790 |
Provision (benefit) for income taxes |
|
(1,884 |
) |
|
|
(5,409 |
) |
|
|
(3,920 |
) |
|
|
4,484 |
|
|
|
|
|
|
|
|
|||||||
EBITDA |
|
(106,593 |
) |
|
|
7,527 |
|
|
|
(78,772 |
) |
|
|
87,006 |
|
|
|
|
|
|
|
|
|||||||
Asset impairment |
|
111,358 |
|
|
|
— |
|
|
|
111,358 |
|
|
|
— |
Management fees |
|
362 |
|
|
|
1,055 |
|
|
|
2,787 |
|
|
|
4,893 |
Restructuring expense |
|
2,967 |
|
|
|
4,759 |
|
|
|
20,657 |
|
|
|
8,540 |
Integration costs |
|
— |
|
|
|
67 |
|
|
|
169 |
|
|
|
67 |
Severance costs |
|
160 |
|
|
|
22 |
|
|
|
1,529 |
|
|
|
1,255 |
COVID-19 related costs |
|
138 |
|
|
|
1,865 |
|
|
|
1,301 |
|
|
|
8,464 |
Transaction costs |
|
1,650 |
|
|
|
983 |
|
|
|
8,464 |
|
|
|
3,034 |
|
|
|
|
|
|
|
|
|||||||
Adjusted EBITDA |
$ |
10,042 |
|
|
$ |
16,278 |
|
|
$ |
67,493 |
|
|
$ |
113,259 |
(1) Modivcare accounts for its proportionate share of Matrix's results using the equity method. Matrix's Adjusted EBITDA is not included within
|
|||||||||||||||
Unaudited Reconciliation of Non-GAAP Financial Measures |
|||||||||||||||
Adjusted Net Income and Adjusted Net Income per Common Share: |
|||||||||||||||
(in thousands, except share and per share data) |
|||||||||||||||
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
|
|
|
|
|
||||||||
Income (loss) from continuing operations, net of tax |
$ |
(31,465 |
) |
|
$ |
(2,905 |
) |
|
$ |
(6,289 |
) |
|
$ |
89,614 |
|
|
|
|
|
|
|
|
|
||||||||
Restructuring and related charges (1) |
|
9,970 |
|
|
|
2,901 |
|
|
|
21,185 |
|
|
|
6,179 |
|
Transaction costs (2) |
|
7,152 |
|
|
|
7,919 |
|
|
|
25,588 |
|
|
|
12,619 |
|
Cash settled equity (3) |
|
20 |
|
|
|
9,180 |
|
|
|
9,165 |
|
|
|
16,071 |
|
Stock-based compensation (3) |
|
1,010 |
|
|
|
929 |
|
|
|
4,793 |
|
|
|
3,776 |
|
Equity in net loss (income) of investee |
|
36,826 |
|
|
|
2,734 |
|
|
|
38,250 |
|
|
|
(6,411 |
) |
Intangible amortization expense |
|
16,424 |
|
|
|
6,475 |
|
|
|
44,251 |
|
|
|
16,694 |
|
Transaction-related financing expense |
|
— |
|
|
|
9,000 |
|
|
|
6,630 |
|
|
|
9,000 |
|
COVID-19 related costs |
|
(1,239 |
) |
|
|
855 |
|
|
|
(2,492 |
) |
|
|
1,204 |
|
Tax impact of the CARES Act |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(10,984 |
) |
Tax effected impact of adjustments |
|
(8,896 |
) |
|
|
(8,365 |
) |
|
|
(28,840 |
) |
|
|
(15,900 |
) |
|
|
|
|
|
|
|
|
||||||||
Adjusted Net Income |
$ |
29,802 |
|
|
$ |
28,723 |
|
|
$ |
112,241 |
|
|
$ |
121,862 |
|
|
|
|
|
|
|
|
|
||||||||
Dividends on convertible preferred stock |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,988 |
) |
Income allocated to participating securities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(7,052 |
) |
|
|
|
|
|
|
|
|
||||||||
Adjusted Net Income available to common stockholders |
$ |
29,802 |
|
|
$ |
28,723 |
|
|
$ |
112,241 |
|
|
$ |
112,822 |
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EPS |
$ |
2.11 |
|
|
$ |
2.00 |
|
|
$ |
7.89 |
|
|
$ |
8.25 |
|
|
|
|
|
|
|
|
|
||||||||
Diluted weighted-average number of common shares outstanding |
|
14,149,143 |
|
|
|
14,354,225 |
|
|
|
14,224,302 |
|
|
|
13,683,308 |
|
(1) Restructuring and related charges include severance, organizational consolidation costs and professional fees.
(2) Transaction costs include certain transaction-related expenses, primarily for the Simplura, Care Finders and VRI acquisitions.
(3) Adjusted net income for the three and twelve months ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20220225005097/en/
Investor Relations
(212) 836-9614
kahl@equityny.com
Source:
FAQ
What were Modivcare's fourth quarter 2021 financial results?
What was the adjusted EBITDA for Modivcare in 2021?
What acquisitions did Modivcare complete in 2021?
How did the Matrix investment impact Modivcare's financials?